Category: Medical Professionals

How Mikhail Blagosklonny is Helping Advance Useful Anti-Aging Solutions

Mikhail Blagosklonny is among the most recognizable researchers in the world. He is credited with the advancement of breakthrough therapies that have helped alleviate pain and suffering among cancer patients. Recently, he proposed the use of Rapamycin to slow down the aging process. This is a noteworthy announcement considering that Dr. Mikhail Blagosklonny is an authoritative figure in the fields of cancer and aging.

Mikhail has been one of the greatest proponents of Rapamycin, which is a popular cancer treatment medication. According to him, the drug has successfully helped extend the lifespan of cancer patients besides easing the pain and suffering that is associated with the ailment. He believes that basing on this, the drug can also be successfully used to boost the human immune system thus elongating our lifespan. Visit to read more about Mikhail.

Mikhail’s Thesis

According to Dr. Mikhail Blagosklonny, Rapamycin has the ability to slow down aging thus enabling human beings to live longer because it inhibits mTOR, a chemical compound whose production increases with age. In as much as this compound isn’t entirely harmful, it is not important as it is during a human being’s development stage. With time, it promotes the aging process besides causing a host of health complications.

By using Rapamycin, you not only slow down the aging process, but also strengthen your immunity. This goes a long way in delaying the onset of most illnesses that come as a result of aging including cancerous infections. This helps to prolong life. Research similarly indicates that animals that have been treated using Rapamycin tend to live longer than those that are not treated with the drug. This clearly shows that it has the ability to extend human life.

Rapamycin works by inactivating genes that enhance the rate of aging among human beings. In addition, it suppresses cellular senescence, a hormone that greatly contributes to aging. Besides this, the drug helps prevent Parkinson’s disease and Alzeimer, which are associated with aging. In as much as Rapamycin is currently used in cancer treatment only, Mikhail’s research is likely to see it used for a wide range of purposes in coming years. Read more on

Dr. Mikhail Blagosklonny in Brief

Mikhail Blagosklonny has established himself as one of the most passionate cancer researchers. He has made an immense contribution to oncology. For decades, he has also been a priceless asset to the pharmaceutical and medical field. His pioneering studies have helped millions of cancer patients in particular to access affordable cancer treatment.

At the moment, Mikhail works at Roswell Park Cancer Institute, a prominent facility that seeks to unravel cancer therapies. He is an oncology professor at the institution besides leading several research teams. Dr. Blagosklonny previously served as a medical doctor before venturing into the field of oncology. He similarly served on the management board of notable cancer research bodies.

JeanMarie Guenot: Pushing The Envelope of Innovation


JeanMarie Guenot, who is a business executive, has greatly impacted the health community. She has received her PhD from the University of California, San Francisco. She also received her MBA from the University of Pennsylvania- The Wharton School. Indeed, her ongoing work continues to improve the lives of others. Guenot has over 20 years of experience focused in the pharmaceutical and biotechnology industry. In fact, her experience has allowed her to work in all stages of companies, which has allowed her to really put her skills to use. For instance, she has worked with public and private, pharmaceutical R&D, and business development just to name a few.


For Guenot, it all started with a career at Atlas Venture, where she would manage venture capitalist investments and simultaneously build life science companies. JeanMarie Guenot is dedicated to the advancement of health technology. In fact, Dr. Guenot founded an SKS Ocular, which she also built and ran. The SKS Ocular is a start-up ophthalmic company incubator that is focused on dry AMD, sustained release ocular drug delivery technologies, and macular degeneration. She has also headed other companies such as Hoffmann-La Roche in Basel and Shangai, where she was a business advisor. In addition, she was Vice President of Corporate and Business Development at PDL BioPharma. Here, she led licensing mergers and acquisitions, and alliance management for their commercial product portfolios.


Currently, Guenot is the President and CEO of Amphivena Therapeutics Inc. Amphivena provides services that are focused on drug discoveries that are integral to the advancements of the health industry. Specifically, Amphivena develops tetravalent T-cell redirecting bispecific antibodies. This is for the treatment of hematologic malignancies. In addition, Amphivena Therapeutics currently has a leading drug candidate, AMV-564, which is a CD33/CD3-targeting treatment for acute Myeloid Leukemia or AML.


JeanMarie Guenot has indeed been a key component in creating innovative health technology. Her knowledge and experience is invaluable in that it has continuously aided in the longevity of many people’s lives. Certainly, Guenot has shown the world just how far science can take this world and will continue to push the envelope of innovation for the betterment of the world.  Read more about her company’s new partnership on Takeda’s website here.